BIOYF:OTC-BioSyent Inc (USD)

COMMON STOCK | Drug Manufacturers-Specialty & Generic | OTC

Last Closing Price

USD 5.95

Change

0.00 (0.00)%

Market Cap

USD 0.08B

Avg Analyst Target

N/A

Avg User Target

USD
Average Analyst Rating

N/A

Fundamental Analysis

Verdict

About

BioSyent Inc., a specialty pharmaceutical company, sources, acquires or in-licenses, develops, and sells pharmaceutical and other healthcare products in Canada and internationally. Its products include FeraMAX 150, an oral hematinic; FeraMAX Powder, a water soluble oral iron supplement, which helps the body form red blood cells; and FeraMAX Pd Therapeutic 150 for the prevention and treatment of iron deficiency anemia. It also offers Cathejell, a product indicated for surface anesthesia and lubrication during various procedures, including cystoscopy, catheterization, endourethral operation, endoscopy, proctoscopy, rectoscopy, and tracheal intubation, as well as used for the symptomatic treatment of pain in connection with cystitis and urethritis; Aguettant System for pre-filled syringes that are used for various injectable medications in hospital and acute care settings; RepaGyn, a vaginal suppository for the healing of the vaginal mucosa, as well as for the treatment of vaginal dryness caused by menopause, stress, and chemotherapy; Proktis-M, a rectal suppository for the healing of the anus and rectum; and Cysview, an adjunct to white-light cystoscopy for the detection and management of non-muscle invasive papillary bladder cancer. In addition, it provides Combogesic for moderate acute pain and reduction of fever in adults; Protect-It, a non-chemical food-safe grain insecticide product used as a preventative treatment against insect infestations in stored grains; and Tibella, a hormone replacement therapy to treat vasomotor symptoms due to estrogen deficiency. The company sells its products through wholesalers and retail pharmacy chains. The company was formerly known as Hedley Technologies Inc. and changed its name to BioSyent Inc. in June 2006 to reflect its forward focus on the pharmaceutical market. BioSyent Inc. was incorporated in 2006 and is headquartered in Mississauga, Canada.

Company Website : http://www.biosyent.com

Address : 2476 Argentia Road, Mississauga, ON, Canada, L5N 6M1

Fiscal Year End : December

Currency: USD

Country : USA

Technical Indicators

Beta : 1.04

52 Week High : 7.71

52 Week Low : 4.28

200 Day Moving Average : 6.16

50 Day Moving Average : 6.49

Shares Held By Insiders : 38.75%

Shares Held by Institutions : 12.79%

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2021-07-22 )

Largest Industry Peers for Drug Manufacturers-Specialty & Generic

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
MKKGY MERCK Kommanditgesellschaft au..

+0.29 (+0.73%)

 USD86.27B 32.06 18.42
MKGAF MERCK Kommanditgesellschaft au..

N/A

 USD85.18B 31.74 18.56
TKPHF Takeda Pharmaceutical Company ..

+0.52 (+1.57%)

 USD52.46B 15.26 0.08
SFOSF Shanghai Fosun Pharmaceutical ..

+0.19 (+2.11%)

 USD28.09B 37.28 4.93
ESALF Eisai Co., Ltd

N/A

 USD26.94B 70.28 0.25
ESALY Eisai Co., Ltd

+0.13 (+0.15%)

 USD24.14B 62.98 0.25
SGIOF Shionogi & Co., Ltd

N/A

 USD16.08B 16.07 0.08
SGIOY Shionogi & Co., Ltd

+0.06 (+0.42%)

 USD16.04B 15.87 0.08
MTZPY Mitsubishi Tanabe Pharma Corpo..

N/A

 USD10.43B 79.00 0.21
TEVJF Teva Pharmaceutical Industries..

+0.20 (+2.35%)

 USD9.37B 900.00 16.02

ETFs Containing BIOYF

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Drug Manufacturers-Specialty & Generic)		 Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -4.65% 34% F 29% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -4.65% 33% F 28% F
Trailing 12 Months  
Capital Gain 41.00% 54% F 54% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 41.00% 53% F 53% F
Trailing 5 Years  
Capital Gain -9.01% 45% F 37% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -9.01% 44% F 36% F
Average Annual (5 Year Horizon)  
Capital Gain 6.31% 41% F 41% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 6.31% 39% F 38% F
Risk Return Profile  
Volatility (Standard Deviation) 41.52% 79% C+ 55% F
Risk Adjusted Return 15.20% 51% F 36% F
Market Capitalization 0.08B 73% C 49% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Drug Manufacturers-Specialty & Generic)		 Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 24.39 26% F 33% F
Price/Book Ratio 3.50 42% F 33% F
Price / Cash Flow Ratio 10.95 13% F 18% F
EV/EBITDA 9.40 41% F 37% F
Management Effectiveness  
Return on Equity 15.01% 88% B+ 82% B-
Return on Invested Capital 14.01% 77% C+ 79% C+
Return on Assets 10.48% 96% A 94% A
Debt to Equity Ratio N/A N/A N/A N/A N/A
Technical Ratios  
Short Ratio N/A N/A N/A N/A N/A
Short Percent N/A N/A N/A N/A N/A
Beta 1.04 47% F 43% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

No discussions yet

User / Independent Analyst Ratings

User Name Target Rating Target Horizon (Months) Target Price User Analysis Date Comment

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters then its peers, placing it in the top quartile.

Superior capital utilization

The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

High Gross Profit to Asset Ratio

This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.

What to not like:
Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Low Revenue Growth

This stock has shown below median revenue growth in the previous 5 years compared to its sector